Logo image of TRAW

TRAWS PHARMA INC (TRAW) Stock Fundamental Analysis

NASDAQ:TRAW - Nasdaq - US68232V8845 - Common Stock - Currency: USD

1.6  -0.02 (-1.23%)

After market: 1.69 +0.09 (+5.62%)

Fundamental Rating

2

Taking everything into account, TRAW scores 2 out of 10 in our fundamental rating. TRAW was compared to 194 industry peers in the Pharmaceuticals industry. While TRAW seems to be doing ok healthwise, there are quite some concerns on its profitability. TRAW is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year TRAW has reported negative net income.
In the past year TRAW has reported a negative cash flow from operations.
TRAW had negative earnings in each of the past 5 years.
In the past 5 years TRAW always reported negative operating cash flow.
TRAW Yearly Net Income VS EBIT VS OCF VS FCFTRAW Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 2024 -10M -20M -30M -40M -50M

1.2 Ratios

Looking at the Return On Assets, with a value of -181.55%, TRAW is doing worse than 89.12% of the companies in the same industry.
TRAW's Return On Equity of -576.80% is on the low side compared to the rest of the industry. TRAW is outperformed by 78.76% of its industry peers.
Industry RankSector Rank
ROA -181.55%
ROE -576.8%
ROIC N/A
ROA(3y)-116.91%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
TRAW Yearly ROA, ROE, ROICTRAW Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 2024 0 100 -100 -200

1.3 Margins

TRAW does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
TRAW Yearly Profit, Operating, Gross MarginsTRAW Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023 2024 -5K -10K -15K -20K

More info and screens

5

2. Health

2.1 Basic Checks

TRAW does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, TRAW has more shares outstanding
There is no outstanding debt for TRAW. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
TRAW Yearly Shares OutstandingTRAW Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2024 1M 2M 3M
TRAW Yearly Total Debt VS Total AssetsTRAW Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 2024 10M 20M 30M 40M 50M

2.2 Solvency

Based on the Altman-Z score of -49.45, we must say that TRAW is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -49.45, TRAW is not doing good in the industry: 92.23% of the companies in the same industry are doing better.
There is no outstanding debt for TRAW. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -49.45
ROIC/WACCN/A
WACC9.94%
TRAW Yearly LT Debt VS Equity VS FCFTRAW Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 2024 0 20M -20M 40M

2.3 Liquidity

TRAW has a Current Ratio of 1.81. This is a normal value and indicates that TRAW is financially healthy and should not expect problems in meeting its short term obligations.
TRAW's Current ratio of 1.81 is on the low side compared to the rest of the industry. TRAW is outperformed by 64.25% of its industry peers.
TRAW has a Quick Ratio of 1.81. This is a normal value and indicates that TRAW is financially healthy and should not expect problems in meeting its short term obligations.
TRAW has a Quick ratio of 1.81. This is in the lower half of the industry: TRAW underperforms 60.62% of its industry peers.
Industry RankSector Rank
Current Ratio 1.81
Quick Ratio 1.81
TRAW Yearly Current Assets VS Current LiabilitesTRAW Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2024 10M 20M 30M 40M 50M

More info and screens

4

3. Growth

3.1 Past

TRAW shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -798.36%.
TRAW shows a small growth in Revenue. In the last year, the Revenue has grown by 0.44%.
EPS 1Y (TTM)-798.36%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%135.31%
Revenue 1Y (TTM)0.44%
Revenue growth 3Y0%
Revenue growth 5YN/A
Sales Q2Q%1.79%

3.2 Future

TRAW is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 41.24% yearly.
TRAW is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 14.21% yearly.
EPS Next Y76.99%
EPS Next 2Y41.24%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year0%
Revenue Next 2Y14.21%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
TRAW Yearly Revenue VS EstimatesTRAW Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2M 4M 6M
TRAW Yearly EPS VS EstimatesTRAW Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 -50K -100K -150K

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

TRAW reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for TRAW. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TRAW Price Earnings VS Forward Price EarningsTRAW Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TRAW Per share dataTRAW EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -20 -40 -60 -80 -100

4.3 Compensation for Growth

TRAW's earnings are expected to grow with 41.24% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y41.24%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

TRAW does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

TRAWS PHARMA INC

NASDAQ:TRAW (7/18/2025, 8:16:26 PM)

After market: 1.69 +0.09 (+5.62%)

1.6

-0.02 (-1.23%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)05-13 2025-05-13
Earnings (Next)08-13 2025-08-13
Inst Owners12.76%
Inst Owner Change0%
Ins Owners7.76%
Ins Owner Change-24.04%
Market Cap8.90M
Analysts82.86
Price Target153 (9462.5%)
Short Float %6.57%
Short Ratio0.16
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-4.41%
Min Revenue beat(2)-6.86%
Max Revenue beat(2)-1.96%
Revenue beat(4)0
Avg Revenue beat(4)-4.83%
Min Revenue beat(4)-6.86%
Max Revenue beat(4)-1.96%
Revenue beat(8)0
Avg Revenue beat(8)-10.3%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 39.19
P/FCF N/A
P/OCF N/A
P/B 1.48
P/tB 1.48
EV/EBITDA N/A
EPS(TTM)-101.75
EYN/A
EPS(NY)-0.83
Fwd EYN/A
FCF(TTM)-5.54
FCFYN/A
OCF(TTM)-5.54
OCFYN/A
SpS0.04
BVpS1.08
TBVpS1.08
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -181.55%
ROE -576.8%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-116.91%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.81
Quick Ratio 1.81
Altman-Z -49.45
F-Score2
WACC9.94%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-798.36%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%135.31%
EPS Next Y76.99%
EPS Next 2Y41.24%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)0.44%
Revenue growth 3Y0%
Revenue growth 5YN/A
Sales Q2Q%1.79%
Revenue Next Year0%
Revenue Next 2Y14.21%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-28.53%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year79.79%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-66.01%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-66.14%
OCF growth 3YN/A
OCF growth 5YN/A